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Abstract
Background: Ten uncommon natural type 3/type 2 intertypic poliovirus recombinants were isolated from stool specimens
from nine acute flaccid paralysis case patients and one healthy vaccinee in China from 2001 to 2008.
Principal Findings: Complete genomic sequences revealed their vaccine-related genomic features and showed that their
first crossover sites were randomly distributed in the 39 end of the VP1 coding region. The length of donor Sabin 2
sequences ranged from 55 to 136 nucleotides, which is the longest donor sequence reported in the literature for this type of
poliovirus recombination. The recombination resulted in the introduction of Sabin 2 neutralizing antigenic site 3a (NAg3a)
into a Sabin 3 genomic background in the VP1 coding region, which may have been altered by some of the type 3-specific
antigenic properties, but had not acquired any type 2-specific characterizations. NAg3a of the Sabin 3 strain seems atypical;
other wild-type poliovirus isolates that have circulated in recent years have sequences of NAg3a more like the Sabin 2 strain.
Conclusions: 10 natural type 3/type 2 intertypic VP1 capsid-recombinant polioviruses, in which the first crossover sites were
found to be in the VP1 coding region, were isolated and characterized. In spite of the complete replacement of NAg3a by
type 2-specific amino acids, the serotypes of the recombinants were not altered, and they were totally neutralized by
polyclonal type 3 antisera but not at all by type 2 antisera. It is possible that recent type 3 wild poliovirus isolates may be a
recombinant having NAg3a sequences derived from another strain during between 1967 and 1980, and the type 3/type 2
recombination events in the 39 end of the VP1 coding region may result in a higher fitness.
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Introduction
Polioviruses, the causative agents of acute paralytic poliomyeli-
tis, have three serotypes and are members of the human
enterovirus C species of Enterovirus genus in the Picornaviridae family
[1]. Polioviruses are small, nonenveloped human enteroviruses in
which the virion consists of 60 copies of each of four capsid
proteins (VP4 to VP1) surrounding a 7,500 nucleotide (nt) positive-
sense, single-stranded polyadenylated RNA genome. The viral
RNA contains a long, open reading frame flanked by a 59-
untranslated region (UTR) and a 39-UTR. A single polyprotein
translated from the RNA strand is first cleaved into three
polyprotein precursors: P1, P2, and P3. P1 is processed to yield
four capsid proteins: VP4, VP2, VP3, and VP1. P2 and P3 are the
precursors of nonstructural proteins: 2A to 2C and 3A to 3D [2].
The trivalent oral polio vaccine (OPV) contains three different
poliovirus serotypes (type 1, 2, and 3). The use of OPV permits
coinfection of the human gut cells with type 1, type 2, and type 3
vaccine strains, and thus providing favorable conditions for
intertypic recombination. In fact, recombination is a very frequent
phenomenon in poliovirus evolution and has been frequently
found in patients with vaccine-associated paralytic poliomyelitis
(VAPP) [3,4,5]. Although OPV is safe, it can circulate silently in
the population with low vaccine coverage for a few months and
then revert from an attenuating pattern to a neurovirulent one
(vaccine-derived polioviruses, VDPVs) to cause an outbreak
[6,7,8,9,10,11]. Circulating VDPVs (cVDPVs) represent strains
that show #99% VP1 coding region sequence homology to the
ancestral Sabin strains and can cause sustained person to person
transmission [11,12]. Most of the cVDPVs strains, except Chinese
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as unidentified recombinant noncapsid sequences; these sequences
are thought to be derived from human enterovirus C species by
recombination [6,7,8,9]. Two genetic characteristics, nucleotide
mutations at key neurovirulence determination sites and genetic
rearrangements with human enterovirus C species, seem to
underlie the occurrence of poliomyelitis outbreaks associated with
cVDPVs [7,12,13].
While the genetic variability of polioviruses is mostly due to
nucleotide substitutions resulting from a high error frequency
during the replication of the viral RNA [14], genetic changes in
polioviruses can also occur by molecular genomic rearrangement
during virus replication [15]. Poliovirus genomic rearrangement
frequently takes place through homologous RNA recombination
and mainly in the nonstructural coding regions of the viral
genome. The frequency of recombination is about 2%, 53%, and
79% of poliovirus type 1, 2 and 3, respectively, and shows that the
frequency depends strongly on the serotype of polioviruses [16].
Most crossover sites of the type 2 recombinants (S2/S1 and S2/S3
recombinants) lie in the P3 coding region, and most crossover sites
of type 3 recombinants (S3/S1 and S3/S2 recombinants) are
located in the P2 coding region [15,17]. On the other hand, the
crossover sites of very few type 3 recombinants (all were S3/S2
recombinants) [18,19,20,21] and only 1 type 2 recombinant (S2/
S3 recombinant) [5], are located in the P1 coding region.
In this study, we describe 10 different natural type 3/type 2
capsid-recombinant polioviruses isolated from nine acute flaccid
paralysis (AFP) case patients and one healthy vaccinee during the
virological surveillance period 2001–2008 in China. Primary
characterization of these isolates revealed that the first crossover
sites of these 10 isolates were all in the VP1 coding region. This
observation led us to study the primary structure of the crossover
sites and the genetic and phenotypic properties of these poliovirus
chimeras.
Results
Primary characterization of the virus isolates
All 10 virus isolates were completely neutralized with polyclonal
antisera specific for type 3 but could not be neutralized with
antisera for type 2. Thus, they were all identified as type 3
polioviruses. Intratypic differentiation (ITD) tests were performed
by two different methods. Polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) ITD tests revealed
typical Sabin 3 restriction patterns except for one strain
(CHN6356) that showed an atypical non Sabin-like (NSL) pattern.
In the enzyme-linked immunosorbent assay (ELISA) ITD tests,
four isolates were identified as Sabin-like (SL), and two isolates
(CHN5275 and CHN6053) were identified as double reactive
virus (DRV), which indicated that they reacted with both Sabin 2-
specific and type 2 wild poliovirus-specific cross-absorbed rabbit
antisera. The results of ELISA ITD were not available for another
four virus isolates due to the change of the ITD testing algorithm
used in the laboratory (Table 1).
The entire VP1 coding sequences of 10 poliovirus isolates
revealed their uncommon genomic intertypic (type 3/type 2)
recombinants with crossover sites within the VP1 capsid-coding
region. The last 55 to 136 nucleotides at the 39 end of the VP1
coding region were found to have high similarity (0–1 nucleotide
substitutions) to the Sabin 2 strain, while the rest of the VP1 coding
region had high similarity to the Sabin 3 strain (1–4 nucleotide
substitutions, and 99.37–99.87%), which showed their vaccine-
related genomic features and revealed that their crossover sites
were all located in the VP1 coding region (Fig. 1).
Reversions of important neurovirulence determination
sites
Complete genomic sequencing of 10 natural type 3/type 2
intertypic vaccine-related poliovirus capsid recombinants with the
first crossover sites within the VP1 coding region (hereafter, VP1
capsid recombinants) showed that their genomes were collinear
with that of the Sabin 3 strain and that several mutations were
scattered throughout the genomes. The nucleotide substitutions
that had been identified as the principal determinants of the
attenuated phenotype of the Sabin 3 strain had reverted through a
U-to-C transition at nt472 in the 59-UTR region and a C-to-U
transition at nt2493 in the VP1 coding region, leading to a Thr-to-
Ile amino acid substitution of residue 6 of VP1 in all 10 isolates.
Strain CHN11185h also exhibited a transition U-to-C reversion at
nt2034 in the VP3 coding region, another important neuroviru-
lence determinant of type 3 polioviruses, which leads to a Phe-to-
Ser amino acid substitution of residue 91 of VP3 [22,23] (Table 2).
Table 1. Primary characterization of natural VP1 capsid recombinants isolated from AFP case patients and a healthy child.
Virus
isolates
Accession
numbers Source*
Age(yr)/
Sex
OPV
history Dates of Intratypic differentiation {
Last OPV Onset Sampling PCR-RFLP ELISA
CHN5275 FJ859183 AFP case 0.8/F 3 11-Jun-2001 8-Aug-2001 14-Aug-2001 SL DRV
CHN6053 FJ859184 AFP case 1.6/M 3 Unknown 28-Jan-2002 26-Feb-2002 SL DRV
CHN6060 FJ859185 AFP case 0.7/M 1 5-Dec-2001 24-Jan-2002 4-Feb-2002 SL SL
CHN6213 FJ859186 AFP case 0.8/M 1 Unknown 20-May-2002 26-May-2002 SL SL
CHN6218 FJ859187 AFP case 1.5/M 1 5-Dec-2001 29-Jun-2002 3-Jul-2002 SL SL
CHN6356 FJ859188 AFP case 0.4/M 2 15-Aug-2002 6-Sep-2002 10-Sep-2002 NSL SL
CHN11144 FJ859189 AFP case 0.4/F 1 16-Jun-2007 17-Jul-2007 27-Jul-2007 SL ND
CHN11185h FJ859190 Healthy vaccinee 1.0/M 1 Unknown — 1-Apr-2007 SL ND
CHN12092 FJ859191 AFP case 3.2/M 3 16-Nov-2005 9-Sep-2008 9-Sep-2008 SL ND
CHN12121 FJ859192 AFP case 0.3/M 1 1-Jul-2008 15-Aug-2008 22-Aug-2008 SL ND
*AFP: Acute flaccid paralysis.
{SL: Sabin like; NSL: non Sabin-like; DRV: Double Reactive Virus; ND: not done.
doi:10.1371/journal.pone.0015300.t001
Natural Type3/Type2 Capsid Poliovirus Recombinant
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The results of the ELISA ITD method showed that strains
CHN5275 and CHN6053 were two antigenic variants of the
Sabin 3 strain; however, all 10 isolates were completely neutralized
with polyclonal antisera to type 3 poliovirus but not with type 2
poliovirus antisera, according to the standard procedure [24]. The
amino acid sequences within or near the predicted neutralizing
antigenic (NAg) sites [25] were aligned with 10 VP1 capsid
recombinants, Sabin 3 strain and its neurovirulent precursor
(Leon/USA/1937), Sabin 2 strain, and some type 3 wild
polioviruses circulating in different parts of the world during the
period 1960–2004. There were four amino acid substitutions in
the NAg sites among these VP1 capsid recombinants: One
substitution was in NAg1 (strain CHN6356, VP1-98: Arg to Gln),
the second in NAg2 (strain CHN11144, VP2-165: Ala to Thr), the
third in NAg3a (strain CHN12092, VP3-59: Ser to Gly), and the
fourth in NAg3b (strain CHN6053, VP3-78: Ser to Phe). In
addition, the whole NAg3a (VP1-286 to VP1-290) in the VP1
Figure 1. Nucleotide acid alignment of putative parental strains (P2/Sabin strain and P3/Sabin strain) and 10 type 3/type 2
intertypic VP1 capsid recombinants. The yellow open rectangles indicated possible crossover sites.
doi:10.1371/journal.pone.0015300.g001
Natural Type3/Type2 Capsid Poliovirus Recombinant
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acid sequences (Fig. 1).
Interestingly, the NAg3a amino acid in the VP1 protein of type
3 wild polioviruses that were circulating throughout the world after
1980 were similar to that of the Sabin 2 strain, and the amino acid
sequences were identical between VP1-286 and VP1-289. Type 3
wild polioviruses isolated from Angola and Tunisia also have the
same residues of VP1-290, and type 3 wild polioviruses isolated
from Nigeria, India, Pakistan, and Afghanistan, where wild
polioviruses are still circulating, have a different residue at VP1-
290 (from Thr to Ala). The neurovirulent precursor of Sabin 3
(Leon/USA/1937) also had a Lys residue at VP1-286 that was
identical to that of the Sabin 2 strain (Fig. 2).
Recombination features of the VP1 capsid recombinants
Eight of the ten VP1 capsid recombinants (strains CHN5275,
CHN6053, CHN6060, CHN6213, CHN6218, CHN6356,
CHN1185h, and CHN12092) were found to have recombination
in two crossover sites: The 59 part of the genome was the Sabin 3
sequence; the middle part was the Sabin 2 sequence; and the 39
part was the Sabin 3 sequence (S3/S2/S3). The first crossover sites
were located in the VP1 coding region, and the second crossover
sites were in the P3 region but at different positions, which could
be identified in all four nonstructural coding regions (3A, 3B
VPg, 3C
or 3D
Pol) (Fig. 3 and Fig. 4).
Strain CHN12121 was simpler in that it had only one crossover
site located between nt3260 and nt3261 in the VP1 coding region;
the 59 part of the genome was the Sabin 3 sequence, and the 39
part was the Sabin 2 sequence (S3/S2) (Fig. 3 and Fig. 4).
Strain CHN11144 was a rare and complicated multi-recombi-
nant poliovirus, and its genomic organization was characterized as
a S3/S2/S1/S2/S1 tetra-recombinant. The complete genomic
sequences revealed the presence of four crossover sites. The first
was from a S3/S2 recombination event with the crossover site
located between nt3233 and nt3240 in the VP1 coding region,
while the second crossover site was from a S2/S1 recombination
event located between nt5156 and nt5157 in the 3A coding region.
The third and the fourth crossover sites were from S1/S2 and S2/
S1 recombination events, with the two crossover sites located in
nt6116–6126 and nt6726 in the 3D coding region, respectively
(Fig. 3 and Fig. 4).
Although the numbers and positions of crossover sites were
different among the 10 VP1 capsid recombinants, they all had the
first crossover sites located in the VP1 coding region. The lengths
between the crossover sites and the 39 end of the VP1 coding
region ranged from 55 to 136 nucleotides, and the crossover sites
of strains CHN6218, CHN11144, CHN11185h, and CHN12092
were located between nt3233 and nt3240, which produced the
longest lengths of donor Sabin 2 genome sequences in the
literature for this type of poliovirus recombination by now
(numbering refers to the Sabin 3 genomic sequences, GenBank
accession number AY184221) (Fig. 1).
Although different lengths of nucleotides (55 to 136 nucleotides)
were introduced in VP1 coding region in each of the recombinant
isolates, four amino acid changes (VP1-286: Arg to Lys, VP1-287:
Asn to Asp, VP1-288: Asn to Gly, and VP1-290: Asp to Thr) in
Nag3a were introduced among these ten VP1 capsid recombi-
nants, which lead the whole NAg3a of these ten recombinants
were completely replaced by Sabin 2-specific amino acid
sequences.
Temperature sensitivity
All 10 VP1 capsid recombinants were compared to P3/Sabin
strain as regards replication capacity at an elevated temperature
(40uC), and showed different results of temperature sensitivities.
P3/Sabin was temperature sensitive as expected with titer
reduction of more than 2 logarithms at 36uC /40uC, and five
VP1 capsid recombinants (CHN5275, CHN6060, CHN6218,
CHN6356 and CHN12121) appeared similar results as P3/Sabin
strain, while the property of temperature sensitivity of other five
VP1 capsid recombinants showed a definitely lesser effect (titers
reduced less than 2 logarithms at 36uC /40uC), this means that
replication efficiency of them remains the same even at elevated
temperatures (Table 3).
Table 2. Genetic and phenotypic characterizations of natural VP1 capsid recombinants.
Virus isolate
Nucleotide and amino acid of neurovirulence
determinants
Recombination
pattern Evolution of the viruses*
59-UTR VP3 VP1
nt472 nt2034 aa91 nt2493 aa6 Ks (days) Kt (days)
P3/Sabin U U Phe C Thr —— —
CHN5275 C U Phe U Ile S3/S2/S3 0.34 (38 d) 0.27 (88 d)
CHN6053 C U Phe U Ile S3/S2/S3 0.56 (63 d) 0.39 (127 d)
CHN6060 C U Phe U Ile S3/S2/S3 0.47 (53 d) 0.24 (79 d)
CHN6213 C U Phe U Ile S3/S2/S3 0.35 (39 d) 0.24 (79 d)
CHN6218 C U Phe U Ile S3/S2/S3 0.46 (52 d) 0.24 (79 d)
CHN6356 C U Phe U Ile S3/S2/S3 0.35 (39 d) 0.20 (65 d)
CHN11144 C U Phe U Ile S3/S2/S1/S2/S1 0.58 (65 d) 0.36 (118 d)
CHN11185h C C Ser U Ile S3/S2/S3 1.07 (120 d) 0.36 (118 d)
CHN12092 C U Phe U Ile S3/S2/S3 0.46 (52 d) 0.32 (105 d)
CHN12121 C U Phe U Ile S3/S2 0.46 (52 d) 0.20 (65 d)
P3/Leon/37 C C Ser U Ile — — —
Shaded area indicates the nucleotides and amino acids that were identical to the Sabin 3 strain, numbering according to the Sabin 3 strain (GenBank accession no:
AY184221).
doi:10.1371/journal.pone.0015300.t002
Natural Type3/Type2 Capsid Poliovirus Recombinant
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recombinants
The approximate evolution times of the polioviruses were
estimated from the P1/capsid sequence differences between VP1
capsid recombinants and the Sabin 3 reference strain. The
corrected proportion of synonymous substitutions (Ks) was 0.33–
1.07% of synonymous sites in the P1/capsid region (not including
the donor recombinant sequences), and, of the total substitutions
(Kt), was 0.20–0.39%. Under the assumption of constant
nucleotide substitution rates of 3.2% synonymous substitutions
per synonymous sites per year and 1.1% total substitutions per site
per year in the P1/capsid region [26], we estimated that the ages of
the VP1 capsid recombinants were 38–120 days (from the Ks
estimate) and 65–127 days (from the Kt estimate), respectively.
Discussion
Poliovirus is one of the first recognized viruses to undergo
recombination [27]. Recombination has been found frequently in
wild polioviruses, VDPVs, and vaccine-related polioviruses
[5,28,29]. Usually, the first crossover site is in the P2 or P3
nonstructural region and often within the 3D coding region [15].
Natural intertypic capsid recombination between Sabin strains is a
relatively rare phenomenon, possibly due to structural constraints
that maintain the integrity of the capsid shell. The integrity of the
capsid region of poliovirus seems to be very important for
propagation of the viruses themselves. Some in vitro experiments
have shown that if the crossover site is located in the capsid-coding
region, the intertypic recombinant chimera will be nonviable [30];
in addition, some other experiments have shown that, compared
to its parental strains, the intertypic recombinant chimera with the
crossover site in the capsid-coding region is unstable [31].
Some similar intertypic recombinant chimera have been
reported previously [18,19,20,21], but to the best of our
knowledge, 136 nucleotides insert is the longest donor sequence
that has been reported, so the longest poliovirus type 2 insert in the
VP1 coding region of poliovirus capsid recombinant has been
reported herein.
Although the first crossover sites were different from each other
among the 10 VP1 capsid recombinants, they all gained type 2
NAg3a amino acids in the VP1 structure protein in the Sabin 3
background. Although the replacement of NAg3a in these
recombinant viruses could result in partial antigenic changes, as
shown before [18,20], the overall type 3 antigenic structure was
not significantly altered since all virus isolates were readily
neutralized by type 3 polyclonal serum. This meant that NAg3a
may have altered some of the type 3-specific antigenic properties
but that Sabin 3 had not acquired any type 2-specific
characterizations, possibly based on the fact that the inserted
type 2 NAg3a is located on the surface of the virion and is
implicated in receptor binding, allowing more freedom for
aberrant folding [32].
Figure 2. Alignment of amino acid residues of neutralizing antigenic (NAg) sites 1 (VP1: 88–106), 2 (VP2: 163–169; VP2: 268–270; VP1:
220–225), 3a (VP3: 54–61; VP3: 70–74; VP1: 286–291), and 3b (VP2: 71–73; VP3: 75–79) for Sabin 3, its parental strain Leon/USA/1937,
VP1 capsid recombinants, Sabin 2, and some wild-type polioviruses circulated worldwide after 1960 (GenBank accession numbers:
EU918372, EU918375, EU918374, FJ914252, FJ842179, AM707037, AM707033, AY221236, AY189887, AY221231, AY221227,
AY221224, and AY741367). The rectangle shows NAg3a displacement in VP1 from Sabin 3 to Sabin 2 due to the recombination. The dashed
rectangle shows NAg3a of type 3 wild polioviruses circulated after 1980.
doi:10.1371/journal.pone.0015300.g002
Natural Type3/Type2 Capsid Poliovirus Recombinant
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other type 3 wild poliovirus isolates that have circulated worldwide
in recent years (after 1980) have sequences of NAg3a more like the
Sabin 2 strain. But the type 3 wild poliovirus isolates from earlier
year (before 1967) still have sequences of NAg3a more like the
Sabin 3 strain. The possibility exist that recent type 3 wild
poliovirus isolates may be a recombinant having NAg3a sequences
derived from another strain during between 1967 and 1980. It
seems likely, but is hard to prove, that perhaps the type 3/type 2
recombination events in the 39 end of VP1 coding region may have
a higher fitness.
The results of age estimation guided us towards the reconstruc-
tion of the potential histories of these clinical isolates. OPV strains
had replicated in the human gut for 38–120 days (from the Ks
estimate) and for 65–127 days (from the Kt estimate) after the
initial OPV doses were given. Based on the fact that type 2 and
type 3 vaccine viruses can replicate and be excreted by
immunocompetent vaccinees for about 3 months after vaccination
[33] and considering the small dispersion of ages, the possibility
that each particular recombination event occurred in the person
from whose stool specimen the virus was isolated cannot be
excluded. During the short time period, nucleotide substitutions
and genetic exchanges were selected very quickly, probably as a
response to different selective advantages, to increase the fitness of
the Sabin strains for replication in the human gut by preventing
the accumulation of harmful mutations.
Figure 3. Schematics of the genomes for the 10 type 3/type 2 intertypic VP1 capsid recombinants. (a): Schematic genetic organization of
Sabin 3 reference strain (GenBank accession number AY184221). The single open reading frame, flanked by 59-UTR and 39-UTR, is indicated by a
rectangle. (b): Structures of 10 type 3/ type 2 Sabin intertypic capsid recombinants; type 1, type 2, and type 3 poliovirus sequences are indicated
(abbreviated as S1, S2, and S3, respectively). Symbol . indicates the location of S3/S2 crossover sites; symbol h indicates the location of S2/S3
crossover sites; symbolN indicates the location of S2/S1 crossover sites; and symbol # indicates the location of S1/S2 crossover sites. The positions of
crossover sites are indicated at the top of each of the symbols.
doi:10.1371/journal.pone.0015300.g003
Natural Type3/Type2 Capsid Poliovirus Recombinant
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used in this study is that this approach assumes a fixed
substitution rate and multiplies it by the estimated number of
nucleotide substitutions (total substitutions or synonymous
substitutions), but in fact, the actual amount of evolution (number
of substitutions) mainly depends on the virus effective population
size inside the host and the frequency of replication. Additionally,
the recombination events would lead to a change in the selection
pressure, and most likely, there would be an increase in selection
resulting in an increased evolutionary rate, meaning that the ages
of the VP1 capsid recombinants may have been overestimated.
This is most obvious in the case of CHN11144, whose estimated
ages (65 days from the Ks estimate or 118 days from the Kt
estimate) are greater than the time from administration of OPV
to sampling (41 days).
All the children had one or more OPV before sampling, and the
intervals between the dates of administration of last OPV and
sampling are from 26 days to 1027 days, which indicated not all
natural VP1 capsid recombinants directly derived from the OPV
strains they received, most likely, some children were affected by
them from environment. There was evidence that, like other
vaccine-like polioviruses, VP1 capsid recombinants could survive
and be detected from the environmental sewage [21].
Genetic attenuation usually decreases viral fitness, and all the
VP1 capsid recombinants had nucleotide substitutions of U-to-C at
nt472 in the 59-UTR region and a transition C-to-U at nt2493,
which resulted in a Thr-to-Ile substitution of residue 6 of VP1, and
these were direct reversions to the neurovirulent precursor of
Sabin 3, Leon/USA/1937. These two nucleotide substitutions
have also been frequently found in type 3 VDPV strains, including
2002 VDPV isolates from sewage in Estonia [34], 2006 iVDPV
isolates from an Iranian child [35], and in the Sabin 3-related
polioviruses [36], which may indicate that these ‘‘hot spots’’ faced
intensive selective pressures as the OPV strain replicated in the
human gut.
Five of the VP1 capsid recombinants (CHN5275, CHN6060,
CHN6218, CHN6356 and CHN12121) did not lose the
temperature-sensitive phenotype of parent P3/Sabin strain. This
result differed to three previously reported capsid recombinants
which had almost entirely lost the temperature sensitivity
[18,19,20], but was similar to a recent report [21], and other
five VP1 capsid recombinants in this study had almost entirely lost
the temperature sensitive phenotype. It had been reported that the
temperature sensitivity phenotype of type 3 poliovirus is mainly
attributable to a difference in residue 91 of the VP3 capsid protein
[37], but this amino acid substitution could not be found in the
VP1 capsid recombinants in this study except strain CHN11185h
(Table 2), and this might explain the preservation of temperature-
sensitive phenotype of the viruses. Besides residue 91 in VP3
capsid region, 11 other amino acid substitutions have been
suggested to be related to temperature sensitivity, four in VP1
region (residues 34, 54, 132 and 263), four in VP2 region
(residues146, 200, 215 and 265), and three in VP3 region (residues
108, 175 and 178) [37]. Among these, the substitution Ala to Thr
or Ala to Val at position 54 in the VP1 capsid region were found in
strains CHN5275, CHN6053 and CHN12092.
In conclusion, 10 natural type 3/type 2 intertypic VP1 capsid-
recombinant polioviruses, in which the first crossover sites were
found to be in the VP1 coding region, were isolated and
characterized. In spite of the complete replacement of NAg3a by
type 2-specific amino acids, the serotypes of the recombinants
were not altered, and they were totally neutralized by polyclonal
type 3 antisera but not at all by type 2 antisera. NAg3a of the
Sabin 3 strain seems atypical; other wild-type poliovirus isolates
that have circulated in recent years have sequences of NAg3a
more like the Sabin 2 strain. It is possible that recent type 3 wild
poliovirus isolates may be a recombinant having NAg3a sequences
derived from another strain during between 1967 and 1980, and
the type 3/type 2 recombination events in the 39 end of the VP1
coding region may result in a higher fitness.
Table 3. Temperature sensitivity of 10 natural type 3/type 2 capsid-recombinant polioviruses.
Growth temperature and virus titer
366C4 0 6C Log titer reduction 366C/406C
Virus strain 8 h p.i. 24 h p.i. 8 h p.i. 24 h p.i. 8 h p.i. 24 h p.i.
P3/Sabin 6.500 8.250 3.250 3.750 3.250 4.500
CHN5275 8.500 8.875 7.000 6.750 1.500 2.125
CHN6053 7.625 8.250 7.500 7.500 0.125 0.750
CHN6060 8.375 8.875 6.875 6.625 1.500 2.250
CHN6213 7.875 8.125 6.750 6.750 1.125 1.375
CHN6218 7.750 7.875 6.125 5.625 1.625 2.250
CHN6356 8.000 7.875 6.125 5.625 1.875 2.250
CHN11144 8.250 8.750 7.125 7.375 1.125 1.375
CHN11185h 8.500 9.000 7.125 7.125 1.375 1.875
CHN12092 8.500 8.500 7.250 7.125 1.250 1.375
CHN12121 8.000 8.375 5.750 5.125 2.250 3.250
*Ks: synonymous substitutions, Kt: total substitutions.
doi:10.1371/journal.pone.0015300.t003
Figure 4. Similarity plot and bootscanning analysis of complete genomes of 10 type 3/type 2 intertypic VP1 capsid recombinants
using a sliding window of 200 nt moving in 20-nt steps. For each plot, the names of viruses of the query sequence were indicated in the
bottom right corner, and for each bootscanning analysis, the names of viruses of the query sequence were indicated in the bottom left corner.
doi:10.1371/journal.pone.0015300.g004
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Stool specimens
This study did not involve human participants and did not
contain human experimentation, the only used material is stool
samples collected from the AFP case patients for the purpose of
public health initiated by World Health Organization and Chinese
Ministry of Health, and the written informed consents from all
participants involved in this study were obtained for the use of
their stool samples. This study has been approved by the second
session of Ethics Review Committee in Chinese Centre for Disease
Control and Prevention.
10 type 3 polioviruses were isolated from nine AFP case
patients (from Jiangxi, Henan, Yunnan, Guangdong, Gansu,
Guizhou, Hubei, and Hebei provinces) and a healthy vaccinee
(from Xizang Autonomous Region) during the period 2001–2008
in China. All the AFP case patients were less than 1.6 years old
when they presented with symptoms, except for one patient from
Hubei province (a 3.2-year-old boy). All of the children with AFP
had at least one dose of OPV after birth; however, it was
unknown when the healthy vaccinee from the Xizang Autono-
mous Region had received a dose of OPV because a written
record of this could not be located. None of the patients with AFP
showed signs of immunodeficiency at the time of presentation.
Two stool specimens were collected from each of the nine AFP
case patients at 24 hours apart within 14 days after onset of
symptoms. One stool specimen was collected from the healthy
vaccinee during an epidemiological survey of OPV coverage in
2007 (Table 1).
Viral isolation and primary identification
RD (Human rhabdomyosarcoma) and L20B (mouse L cell
expressing the human poliovirus receptor) cell lines were used to
isolate viruses from the stool specimens by standard procedures
[24]. All L20B-positive isolates were identified by a micro-
neutralization test with poliovirus type-specific rabbit polyclonal
antisera (National Institute for Public Health and the Environment
[RIVM], Bilthoven, The Netherlands) [24]. Two ITD methods,
both targeting the VP1 coding region, were used to investigate the
wild or vaccine origin of the poliovirus isolates. First, we employed
the PCR-RFLP method, which was based on the genetic properties
of the polioviruses [38]; this method identified a poliovirus as either
typical SL or atypical NSL. We then applied the ELISA method,
which was based on the antigenic properties of the polioviruses[39];
using this method, poliovirus isolates were classified into one of the
following four different groups formed on the basis of antigenic
properties: SL, NSL, DRV, and nonreactive virus (NRV).
Viral RNA extraction and reverse transcription
Viral RNAs were extracted from the viral isolates using a
QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) and
stored at 280uC for further use. 1ml (200U) SuperScript II
ribonuclease H- reverse transcriptase (invitrogen, USA) was used
to produce single stranded cDNA from 5ml of each purified viral
RNA. The cDNA syntheses were primed by 7500A and Q8
(Table 4), respectively, and performed at 42uC for 2h, followed at
60uC for 15 min to inactivate the enzyme. Finally, RNA in an
RNA:DNA hybrid was specifically degraded with 1ml ribonuclease
H (Promega, USA) at 37uC for 30 min.
Table 4. PCR and sequencing primers.
Primer
Nucleotide
position (nt) Primer sequence (5-3) Orientation Reference
0001S48
a GGGGACAAGTTTGTACAAAAAAGCAGGCTTTAAAACAGCTCTGGGGTT Forward [6]
EV/PCR-2 449–473 TCCGGCCCCTGAATGCGGCTAATCC Forward [42]
EV/PCR-1 537–562 ACACGGACACCCAAAGTAGTCGGTCC Reverse [42]
1275S 1275–1294 ACGTGCAGTGTAATGCATCC Forward This study
1511A 1492–1511 TTCCCAGTAACACCCCACAT Reverse This study
1949S 1949–1969 AACACAATGGACATGGTATAG Forward This study
2224A 2205–2224 ACATGTGTGCCCAACATAGC Reverse This study
Y7
a 2397–2419 GGTTTTGTGTCAGCGTGTAATGA Forward [43]
2873A 2853–2873 GAATTCCATGTCAAATCTAGA Reverse This study
3368S 3368–3389 AACGACTTATGGATTTGGACAC Forward This study
Q8
a 3477–3496 AAGAGGTCTCTRTTCCACAT Reverse [43]
4443S 4443–4465 AAYTACATACAGTTCAAGAGCAA Forward [5]
4489A 4468–4489 AAACATACTGGCTCAATACGGT Reverse [6]
5076S 5076–5097 GGTAATTGCATGGAAGCTCTAT Forward This study
5274A 5253–5274 GGTTGATGTTCCTCTCTGTTTG Reverse This study
5904S 5904–5929 GGGATGCATGTYGGIGGGAACGGTTC Forward This study
6097A 6077–6097 GGTTCCTTAACTCCTTCAAAC Reverse [6]
6914S 6914–6934 CTACAAGGGCCTAGATTTAGA Forward [5]
6970A 6951–6970 ATTACATCATCACCATAGGC Reverse This study
7500A
a GGGGACCACTTTGTACAAGAAAGCTGGG(T)24 Reverse [6]
aThe primer pairs Y7/7500A and 0010S48/Q8 are suggested for long distant PCR. The expected amplicons from these are 5.28 kb and 3.57 kb, respectively.
doi:10.1371/journal.pone.0015300.t004
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Two long-distant PCR amplifications (for one virus) were
performed by using the TaqPlus Precision PCR system (Strata-
gene, USA), which consists of a blend of Stratagene cloned Pfu
DNA polymerase (proof reading) and Taq2000 DNA polymerase
(non-proof reading). Reactions contained 5ml of cDNA (see above),
0.1mM of each dNTP, 10ml of TaqPlus buffer, 1.0 ng/mlo fa
forward (0001S48 or Y7) and reverse (Q8 or 7500A) primer
(Table 4), and 5 units TaqPlus enzyme in a 100ml reaction. The
amplification was carried out by 30 times cycling through
temperature levels of 94uC (30 s), 60uC (30 s), and 72uC (6 min),
and followed by another two temperature levels of 94uC (1min)
and 72uC (20 min).
Nucleic acid sequencing
Two long-distant PCR products (for one virus) were purified
using a QIAquick Gel Extraction Kit (Qiagen, Valencia, CA,
USA). Cycle sequencing reactions were carried out using the
version 3.0 of the BigDye terminator chemistry (Applied
Biosystems), using the primers listed in Table 4. Sequencing was
performed in both directions using an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems), and every nucleotide position was
sequenced at least once from each strand. 59 segment sequences
were determined by using the 59 rapid amplification of cDNA ends
core set (Takara Biomedicals) according to the manufacturer’s
instructions.
Location of the crossover sites
The sequences of the isolates were aligned with the reference
strains by using the MEGA program v4.0 (Sudhir Kumar, Arizona
State University, Arizona, USA) [40]; the resulting reference strain
sequences were found to be GenBank sequences under the
accession numbers AY184219, AY184220 and AY184221 for
Sabin 1, Sabin 2 and Sabin 3, respectively. Plots of nucleotide
similarity were created using the SimPlot program v3.5.1 (Stuart
Ray, Johns Hopkins University, Baltimore, Maryland, USA) [41].
The crossover sites were identified as located between the last
nucleotide, differentiating the clinical sequence from the 39 partner
reference sequences, and the first nucleotide, differentiating the
clinical sequence from the 59 partner reference sequence.
Assay for temperature sensitivity
Temperature sensitivities of 10 natural type 3/type 2 capsid-
recombinant polioviruses were assayed on monolayer RD cells in
24-well plates as described before [18]. Briefly, the 24-well plates
were inoculated with 50 ml of undiluted virus stocks (P3/Sabin and
10 VP1 capsid-recombinants). And two different incubators were
used; the temperature of one incubator was adjusted to 36uC
(optimal temperature for virus propagation), while the temperature
of the other incubator was adjusted at 40uC (supraoptimal
temperature for virus propagation). After absorption at 36uCo r
at 40uC for 1 h, the unabsorbed virus inoculums was removed,
100 ml of maintenance medium was added to each well and the
plates were continually incubated at 36uCo ra t4 0 uC, separately.
After 8 h and 24 h post-infection, the plates were harvested, and
the cell culture infectious dose 50% (CCID50) was calculated by
the end-point dilution method on monolayer RD cells in 96-well
plates at 36uC. Virus isolate showing more than 2 logarithms
reduction of the titers at different temperatures was considered to
be temperature sensitive.
Estimation of the date of the initiating OPV dose
The date of the initiating OPV dose for each patient was
estimated from the Ks (synonymous substitutions per synonymous
site) and Kt (all the substitutions per site) values by assuming
evolution rates of 0.032 synonymous substitutions per synonymous
site per year and 0.011 total substitutions per site per year [26].
Nucleotide sequence accession numbers
The complete genomic sequences of 10 natural type 3/type 2
capsid-recombinant polioviruses described in this study were
deposited in the GenBank database under the accession numbers
FJ859183 to FJ859192.
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